Aceso Life Science issues supplemental disclosure on FVTOCI investment valuations and impairments

• Aceso Life Science issued a supplemental annual-results clarification detailing its financial assets at FVTOCI as of March 31, 2026.
• Quan Yu Tai was fully impaired, with fair value written to nil from an HK$ 320 million cost amid PRC court enforcement actions.
• China Pearl FVTOCI fair value fell to HK$ 76 million from an HK$ 170 million cost, reflecting a HK$ 26.4 million unrealized loss.
• Co-Lead recorded an unrealized fair value loss of about HK$ 5.1 million, driven by valuation of underlying private-company assets at zero.
• Goodwill International showed no unrealized fair value loss, with an HK$ 3 million fair value versus an HK$ 45 million investment cost.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aceso Life Science Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260911-12330313), on September 11, 2026, and is solely responsible for the information contained therein.